Complement and complement regulatory proteins as potential molecular targets for vascular diseases.
By-products of complement activation and complement regulatory proteins are increasingly recognized to play an important pathogenic role in a variety of vascular diseases including atherosclerosis, ischemia and reperfusion injury, hyperacute graft rejection, vasculitis, and the vascular complications of human diabetes. "Self" damage by autologous complement is mediated by activation products of the complement cascades or by direct insertion of the membrane attack complex (MAC) into cell membranes. Specifically, insertion of MAC complexes into endothelial cells results in the release of an array of growth factors and cytokines that induces proliferation, inflammation and thrombosis in the vascular wall. This paper reviews complement and complement regulatory proteins with specific focus on the vasculature and vascular diseases; it highlights complement and its regulators as potential targets for the rational design of mechanism-specific drugs for the treatment of some of the most prevalent human diseases.
Acosta
Juan
J
Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, USA.
Qin
Xuebin
X
Halperin
Jose
J
D000818:Animals; D015938:Complement Membrane Attack Complex / Q000502:physiology; D003165:Complement System Proteins / Q000096:biosynthesis / Q000502:physiology*; D016503:Drug Delivery Systems; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D011951:Receptors, Complement / Q000096:biosynthesis / Q000502:physiology*; D014652:Vascular Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D014657:Vasculitis / Q000473:pathology / Q000503:physiopathology
D015938:Complement Membrane Attack Complex; D011951:Receptors, Complement; D003165:Complement System Proteins